SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference

SAE Media Group19 - 20 September 2022, London, United Kingdom.
The Aseptic processing industry has seen consistent growth in recent years, with advances in innovative therapeutics, the introduction of novel techniques and personnel protocols, the integration of robotics and automation in filling lines, and rise of rapid microbiological methods being just a few of the factors driving this growth.

The Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015, and is projected to exceed 12 billion USD in value by next year, then to far surpass a total market value of 50 billion USD before the end of the decade.

Join SAE Media Group to discuss and address the Guidance and Regulation including the EU GMP Annex 1, environmental control delving into the contamination control strategy, Pharma moving forward 4.0 covering data integrity and data consistency, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring

This event is CPD Accredited

Benefits of Attending:

  • Discuss the revisions and the impact of Annex 1 on aseptic manufacturing
  • Explore the applications of rapid micro methods in the manufacture of sterile products
  • Discover a risk-based approach to cleaning and disinfection
  • Delve into case studies of competence in global aseptic manufacturing
  • Uncover the journey of isolation technology in a large biotech pharmaceutical plant
  • Analyse the new abilities of robotics and automation through their integration into aseptic technique

Who Should Attend?

  • Validation Managers
  • Senior Microbiologists
  • Senior QA's and QC's
  • Quality Control Managers
  • Heads of GMP Compliance
  • Quality Assurance Experts
  • Technical Operations Leads
  • Leaders in Sterility Assurance
  • Cleanroom Managers
  • Regulatory Affairs Managers
  • Production Managers
  • Quality Systems Managers
  • Heads of Quality Compliance
  • Process Leaders
  • Senior Auditors
  • Bioprocess Research & Development

Post-Conference Workshop on 21 September 2022

Implementation Strategy of Annex 1 in New or Existing Facilities

Led by: Richard Denk, Senior Consultant Aseptic Processing & Containment, Skan AG

For further information and to register, please visit:
http://www.asepticprocessing.co.uk/WPNWL

About SAE Media Group

SAE Media Group Conferences, based in London, connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges.

Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences.

SAE Media Group (SMG), an subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

SAE Media Group is comprised of two synergistic organizations:

  • SMG Conferences, based in London, produces over 60 high-level networking events worldwide, concentrating on the Aerospace, Defense, Pharmaceutical, and Medic al industries. These events bring together senior government and industry executives/program managers to share knowledge and collaborate on key technology topics including military space, unmanned and autonomous systems, microbiology, biosensors, and much more. SMG’s flagship event, Global MilSatCom, is the world’s premier conference for the military satellite communications market.
  • SMG Media, headquartered in New York City, offers a diverse multimedia network of engineering magazines, e-newsletters, web sites, webcasts, special reports, and custom marketing services. Primary areas of focus include the Aerospace/Defense, Automotive, Commercial Vehicle, Electronics, and Medical sectors, with extensive coverage of cross-industry technologies including batteries/energy storage, sensors, photonics and imaging, advanced manufacturing, robotics, and motion control.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...